Pan Jiesong, Zhao Yikai, Gu Maocheng, Chen Shuqin, Wang Yuxiao, Gao Wen, Li Jian
Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Inflamm Res. 2025 Sep 10;74(1):120. doi: 10.1007/s00011-025-02078-5.
Cardiovascular diseases (CVDs) are a group of conditions that significantly affect human health and are among the leading causes of death and disability worldwide. Clinical trials and basic research have demonstrated that inflammation plays a pivotal role in the development of CVDs. The inflammasome is a critical component of the innate immune system, involved in various inflammatory responses to pathogens and tissue damage. Absent in melanoma2(AIM2), which belongs to the PYHIN Family, is a receptor for intracellular DNA pattern recognition. AIM2 inflammasomes are implicated in the onset and progression of CVDs, activated in atherosclerotic plaques, aortic aneurysms, and damaged myocardium. This review summarizes recent advances in AIM2 research in CVDs, exploring its interactions with other inflammasomes and emphasizing its central role in immune and inflammatory responses. Specifically, the review summarizes the progress of AIM2 inhibitors, in order to critically evaluate the translational potential of such concepts into clinical practices.
心血管疾病(CVDs)是一组严重影响人类健康的病症,是全球死亡和残疾的主要原因之一。临床试验和基础研究表明,炎症在心血管疾病的发展中起关键作用。炎性小体是先天免疫系统的关键组成部分,参与对病原体和组织损伤的各种炎症反应。属于PYHIN家族的黑色素瘤缺失2(AIM2)是一种细胞内DNA模式识别受体。AIM2炎性小体与心血管疾病的发生和发展有关,在动脉粥样硬化斑块、主动脉瘤和受损心肌中被激活。本综述总结了AIM2在心血管疾病研究中的最新进展,探讨了其与其他炎性小体的相互作用,并强调了其在免疫和炎症反应中的核心作用。具体而言,本综述总结了AIM2抑制剂的进展,以便批判性地评估这些概念转化为临床实践的潜力。